AAD2026:GaldermaShowcasesLatestEvidenceSupportingItsFull-Spectrum,Science-DrivenSolutionsforDiverseSkinNeeds
===2026/3/27 11:38:01===
vere frown lines and crow&rsqo;s feet.14
More details on Galderma’s scientific presentations at AAD can be found here.
*RelabotulinumtoxinA, Restylane Skinboosters, and Restylane Shaype for the jawline are investigational products not approved in the United States.
About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology f
=*=*=*=*=*=
当前为第8/17页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页